Latest Articles
Endometrial cancer treatment enters a paradigm shift: expert - koreabiomed.com
Endometrial cancer treatment enters a paradigm shift: expert koreabiomed.com
Published: Dec. 16, 2025, 8:01 a.m.
Phase 3 RUBY Trial: Dostarlimab Combination Prolongs Time to Next Treatment for Endometrial Cancer - Cancer Nursing Today
Phase 3 RUBY Trial: Dostarlimab Combination Prolongs Time to Next Treatment for Endometrial Cancer Cancer Nursing Today
Published: Dec. 15, 2025, 8:24 p.m.
Phase 3 RUBY Trial: Dostarlimab Combination Prolongs Time to Next Therapy for Advanced Endometrial Cancer - Cancer Nursing Today
Phase 3 RUBY Trial: Dostarlimab Combination Prolongs Time to Next Therapy for Advanced Endometrial Cancer Cancer Nursing Today
Published: Dec. 15, 2025, 8:24 p.m.
Endometrial Cancer Remission Rate: What Patients Need to Know in 2025 - Oncodaily
Endometrial Cancer Remission Rate: What Patients Need to Know in 2025 Oncodaily
Published: Dec. 7, 2025, 4:41 p.m.
AQB improves carboplatin sensitivity in endometrial cancer through dual DNA repair modulation: suppression of the p21-E2F1-RAD51 and ATF3-HDAC1-BRCA1 signaling - Nature
AQB improves carboplatin sensitivity in endometrial cancer through dual DNA repair modulation: suppression of the p21-E2F1-RAD51 and ATF3-HDAC1-BRCA1 signaling Nature
Published: Dec. 6, 2025, 7:16 p.m.
Advancing Care in Endometrial Cancer: Exploring Long-Term Outcomes and Real-World Evidence - OncLive
Advancing Care in Endometrial Cancer: Exploring Long-Term Outcomes and Real-World Evidence OncLive
Published: Dec. 5, 2025, 1 p.m.
GSK’s Jemperli now standard in endometrial cancer as reimbursement expands to 1st-line therapy - koreabiomed.com
GSK’s Jemperli now standard in endometrial cancer as reimbursement expands to 1st-line therapy koreabiomed.com
Published: Dec. 1, 2025, 6:49 a.m.
Dissecting endometrial cancer complexity in response to standard and targeted therapies - Nature
Dissecting endometrial cancer complexity in response to standard and targeted therapies Nature
Published: Nov. 28, 2025, 5:08 p.m.
Exploring the combined antiproliferative effects of artesunate and resveratrol in Ishikawa endometrial cancer cells - News-Medical
Exploring the combined antiproliferative effects of artesunate and resveratrol in Ishikawa endometrial cancer cells News-Medical
Published: Nov. 27, 2025, 10:29 a.m.
DESTINY-Endometrial01 Will Examine T-DXd Plus Rilvegostomig or Pembrolizumab in HER2+ pMMR Endometrial Cancer - OncLive
DESTINY-Endometrial01 Will Examine T-DXd Plus Rilvegostomig or Pembrolizumab in HER2+ pMMR Endometrial Cancer OncLive
Published: Nov. 26, 2025, 7:03 p.m.
Link copied to clipboard!